Shots:
- Alvotech has reported that its partner Fuji Pharma has received Japanese approval for three biosimilars: AVT03 (Biosimilar, Ranmark), AVT05 (Biosimilar, Simponi), and AVT06 (Biosimilar, Eylea)
- In Japan, AVT03 (denosumab-biosimilar to Ranmark/Xgeva) was approved for bone lesions from multiple myeloma or solid tumor metastases; AVT05 (golimumab biosimilar to Simponi) for rheumatoid arthritis Pts. who are unresponsive to conventional treatments; and AVT06 (aflibercept biosimilar to Eylea) for AMD, macular edema from retinal vein occlusion, and myopic CNV
- Alvotech and Fuji Pharma’s partnership, established in 2018, now includes four approved biosimilars and two additional candidates under development, which are licensed to Fuji Pharma
Ref: Alvotech | Image: Alvotech| Press Release
Related News:- Alvotech’s Gobivaz (Biosimilar, Simponi) Receives the CHMP’s Positive Opinion to Treat Several Chronic Inflammatory Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
